Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: rare disease mRNA therapeutics - Moderna Therapeutics

Next Previous
Drug Profile

Research programme: rare disease mRNA therapeutics - Moderna Therapeutics

Alternative Names: Antibody messenger RNA therapeutics™; mRNA-3630; MT-004; MT-026; MT-033; MT-039; MT-059; MT-088; MT-104

Latest Information Update: 12 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Class Antihaemorrhagics; RNA
  • Mechanism of Action Alpha-galactosidase stimulants; Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Propionic acidaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haemophilia
  • Discontinued Fabry's disease

Most Recent Events

  • 07 May 2020 Discontinued - Preclinical for Fabry's disease in USA (Parenteral)
  • 05 Feb 2019 Moderna Therapeutics plans to file an IND application for mRNA 3630 for Fabry disease
  • 05 Feb 2019 Moderna Therapeutics plans a clinical trial for Fabry disease for mRNA 3630
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top